Europe
RefluxStop™ is CE marked in Europe. It is currently available in:
- Germany
- United Kingdom
- Switzerland
- Spain
- Italy
- France
- Austria
- Sweden
- Norway
Bringing advanced
technology into the body
Advanced technology has completely changed our daily lives. Implantica has spent over a decade developing and patenting how to bring such advances into the body.
Cornerstone Platform Technologies
Implantica has spent over a decade developing and patenting how to bring technological advances into the body. These technologies are still in development and not yet commercially available.
Smart Medical Implants Pipeline
Medical implants previously seen as unachievable will seek to alleviate unmet medical needs (products in development).
eHealth - The Future of Healthcare
Our implantable eHealth platform, not yet available, is designed to dramatically change healthcare.
Potential paradigm shift in acid reflux treatment
This CE marked device is based on a unique invention that treats the cause of acid reflux, a treatment field affecting 19% of the US and 17% of the EU population weekly1.
Capital Markets Day
September 26, 2023
Press releases
Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success
01.07.2025
| Non regulatory
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval
24.06.2025
| Non regulatory
- 1. Nirwan, J.S., Hasan, S.S., Babar, ZUD. et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep 10, 5814 (2020). https://doi.org/10.1038/s41598-020-62795-1